Acute Myeloid Leukemia with Flt3 Mutation

• FDA approval · 2023-05-22
  FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for RYDAPT (midostaurin) submitted by Novartis Pharmaceuticals Corporation. The approval updates…

• FDA approval · 2021-04-20
  FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for RYDAPT (midostaurin) from Novartis, updating the regulatory status of the product.

• FDA approval · 2018-06-21
  FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approves a supplemental application for RYDAPT (midostaurin) from Novartis Pharmaceuticals; the update expands or modifies the drug’s la…